LSLauren F. Stevenson

Lauren F. Stevenson

*This is an algorithmically generated author record based on publicly available information.

Lauren F. Stevenson has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From detection to decisions: refocusing immunogenicity assessment on clinical relevance

    by Lauren F. Stevenson

    Immunogenicity assessment has changed enormously over the past three decades. Assays have become more sensitive and drug tolerant, technologies increasingly allow us to characterize immune response...

  • Open Access

    Immunogenicity assays are biomarker assays: is the 3-tiered paradigm fit-for-purpose? An illustrative case study

    by Lauren F. Stevenson

    This perspective highlights challenges associated with implementation of the 3-tiered paradigm over the past two-plus decades. A case study is used to illustrate re-analysis of anti-drug antibody (ADA) data from a Phase 1 clinical study of a monoclonal antibody, applying a biomarker-oriented approach. Unlike traditional analyses that focus on "positive" responses defined by statistical cut points, this approach incorporates all data, including "negative" responses, to characterize complete response profiles.By leveraging signal-to-noise (S/N) and raw signal data from the screening tier, the analysis provides a more granular, contextualized view of immunogenicity. Placebo data further inform longitudinal variability within the study population. This approach demonstrably clarifies apparent baseline positivity, distinguishes true treatment-emergent responses, and reveals that some subjects classified as ADA-positive under the traditional paradigm reflect biological variability or low-level, clinically irrelevant responses.Continuous readouts such as S/N enhance interpretation relative to titers and enable earlier insight into response dynamics without requiring additional assay tiers. Collectively, these findings underscore limitations of the current paradigm, including potential inflation of incidence, loss of clinical context, and mischaracterization of program risk. A biomarker-based framework offers an opportunity to generate more informative immunogenicity data more efficiently, supporting improved decision-making and facilitating timely regulatory evaluation.


  • Open Access

    From tiers to truth – a biomarker-based framework for clinically relevant immunogenicity assessment

    by Lauren F. Stevenson

    1. According to the BEST (Biomarkers, EndpointS, and other Tools) Resource, a biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic proce...


  • Open Access

    Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA

    by Devangi Mehta, William Wargin, Stephanie Wallace-Teliz, Lauren F. Stevenson, Greg Rigdon

    The traditional immunogenicity paradigm resulting in anti-drug antibody (ADA) and neutralizing antibody (NAb) positive/negative status and ambiguous or imprecise titers may overlook clinically relevant effects of ADA on pharmacokinetics (PK) and pharmacodynamics (PD). Employing risk-based strategies that integrate PK and PD analyses with ADA magnitude using signal-to-noise (S/N) can provide early insight into potential clinical impact of immunogenicity. In a Phase 1 evaluation of DLX-2323, a humanized single-chain variable fragment (scFv) antibody that binds human IL-1β, ADA-sensitive PK and PD assays were employed to measure DLX-2323 concentration, PD activity, and assess the impact of ADA on PK and PD in healthy participants. The presence of pre-existing ADA was observed in one-third of participants and resulted in high variability of DLX-2323 exposure and PD activity. Pre-existing ADA magnitude correlated with a drug-sustaining impact on PK and PD, with lower clearance (CL/F) and volume of distribution (Vd/F) of DLX-2323 relative to increasing ADA signal. Based on the immunogenicity risk assessment, the use of ADA-sensitive free PK and PD assays to measure in vivo ADA effects on drug exposure and PD activity provided clinically meaningful information that standalone neutralizing antibody assays could not.


  • Best practices in the application of parallelism for biomarker assay validation

    by Lindsay King, John Allinson, Lakshmi Amaravadi, Robert Kernstock, Fabio Garofolo, Michele Gunsior, Barry Jones, Joel Mathews, Robert Nelson, Marc-Olivier Pepin, et al.

    An assessment of parallelism is critical for biomarker assays to confirm whether the assay recognizes the endogenous analyte similarly to the cali


  • Open Access

    Why is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?

    by Yan G. Ni, Lauren F. Stevenson, Lakshmi Amaravadi, Carmen Fernández-Metzler, Lindsay King, Steven P. Piccoli, Amanda Hays, Dhiman Ghosh, Sarah Mitchell Bean, Stephanie Cape, et al.


  • Open Access

    Assessment of Neutralizing Antibody Activity in Clinical Studies: Use of Surrogate Measurements Instead of Stand-alone Assays

    by Michael A. Partridge, Lynn Kamen, Bonnie Wu, Helene Solberg, Jim McNally, Lauren Stevenson, Shalini Gupta, Susana Liu, Weifeng Xu, Yuling Wu, et al.

    Neutralizing antibodies (NAbs) to protein therapeutics have traditionally been assumed to be the most impactful subset of anti-drug-antibodies (ADA). NAbs can block the biotherapeutic from engaging its target impacting efficacy and may also cause serious safety events. Stand-alone NAb assays have been employed to detect neutralizing responses, often with reconfigured versions of other assays. These methods have historically been implemented in registrational trials for all molecules, and in early-stage studies for high risk biotherapeutics. However, data has demonstrated that NAb response and ADA magnitude are highly correlated. Additionally, the use of other markers to identify clinically relevant immunogenicity, such as apparent impact on pharmacokinetics (PK) or pharmacodynamics (PD), has been increasing. This manuscript reviews the available data on clinically meaningful immunogenic responses to biologics and proposes a risk-based strategy to determine if and when to employ a stand-alone NAb assay. For molecules with a high risk of safety consequences of immunogenicity (e.g., biological mimics) a NAb assay is recommended. However, for lower-safety risk molecules a stand-alone NAb assay does not enhance the interpretation of clinical data and is likely not needed. A combination of other assessments including ADA status, magnitude and persistence, PK, and PD (and efficacy) can be used as a surrogate for NAb assay data. Integration of data from all clinical evaluations is recommended by Health Authorities and can provide a more accurate overall assessment of neutralizing activity. This approach identifies clinically impactful downstream readouts of neutralizing activity without the need for a stand-alone NAb assay. Graphical Abstract


  • Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers

    by Karen J. Quadrini, Jiri Aubrecht, Nicholas M. P. King, Carmen Fernandez-Metzler, Yan G. Ni, John-Michael Sauer, Lauren Stevenson, Steven P. Piccoli